Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$2.56 USD
+0.25 (10.82%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $2.55 -0.01 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.56 USD
+0.25 (10.82%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $2.55 -0.01 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -4% and 35.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Markets: Navios Maritime, Coinbase Global, Virtu Financial in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
by Zacks Equity Research
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Cardiff Oncology (CRDF) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 100% and 1.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 39.67% and 1.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?
by Zacks Equity Research
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Cardiff Oncology (CRDF) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 7.41% and 44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.35% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 6.94% and 25.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 10.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Has Cardiff Oncology (CRDF) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cardiff Oncology (CRDF) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 20% and 70.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 4% and 21.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?